Dolutegravir

別名:GSK1349572,S/GSK1349572

Dolutegravir is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM in a cell-free assay, modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.

Dolutegravir化学構造

CAS No. 1051375-16-6

サイズ 価格(税別) 在庫状況
10mM (1mL in DMSO) JPY 53500 国内在庫あり
JPY 40500 国内在庫あり
JPY 55500 国内在庫あり
JPY 98500 国内在庫あり
JPY 295500 国内在庫なし(納期7~10日)

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(27)

カスタマーフィードバック3个实验数据

製品安全説明書

現在のバッチを見る: 純度: 99.85%
99.85

Dolutegravirと併用されることが多い化合物

Bictegravir


Dolutegravir, but not bictegravir represses gene expression and release of adiponectin and leptin in Simpson-Golabi-Behmel syndrome (SGBS) human adipocytes.

Domingo P, et al. Life Sci. 2022 Nov 1;308:120948.

Rilpivirine


Dolutegravir and Rilpivirine are the first dual antiretroviral single tablet combination regimens (STRs) approved by FDA for the maintenance therapy of HIV-1 infection.

Dowers E, et al. HIV AIDS (Auckl). 2018; 10: 215–224.

Lamivudine


Dolutegravir and Lamivudine show lasting effectiveness without increased resistance risk and lower drug-related side effects in adults with HIV-1 infection.

Cahn P, et al. J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):310-318.

Abacavir


Dolutegravir and Abacavir with lamivudine as triple combination therapy is effective and an well tolerated option for the management of HIV-1 infection.

Greig SL, et al. Drugs. 2015 Apr;75(5):503-14.

Atazanavir


Dolutegravir and Atazanavir with Ritonavir is a safe and effective therapy for HIV patients with treatment failure and resistance.

Spagnuolo V, et al. Drug Des Devel Ther. 2019 Jan 24;13:477-479.

Dolutegravir関連製品

シグナル伝達経路

Integrase阻害剤の選択性比較

Cell Data

Cell Lines Assay Type Concentration Incubation Time 活性情報 PMID
HOS Antiviral assay 3 hrs Antiviral activity against HIV-1 harboring wild type integrase infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay, EC50 = 0.0016 μM. 24901667
HEK293T Antiviral assay 2 days Antiviral activity against pseudo Human immunodeficiency virus infected in HEK293T cells after 2 days, IC50 = 0.0017 μM. 23845180
MT4 Antiviral assay 4 to 5 days Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells after 4 to 5 days by bioluminescence assay, IC50 = 0.002 μM. 23845180
HOS Antiviral assay 3 hrs Antiviral activity against raltegravir-resistant HIV-1 harboring integrase N155H mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay, EC50 = 0.0036 μM. 24901667
HOS Antiviral assay 3 hrs Antiviral activity against raltegravir-resistant HIV-1 harboring integrase Y143R mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay, EC50 = 0.0043 μM. 24901667
HOS Antiviral assay 3 hrs Antiviral activity against raltegravir-resistant HIV-1 harboring integrase G140S/Q148H double mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay, EC50 = 0.0058 μM. 24901667
HOS Antiviral assay 3 hrs Antiviral activity against INSTI-resistant HIV-1 harboring integrase R263K mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay, EC50 = 0.011 μM. 24901667
HOS Antiviral assay 3 hrs Antiviral activity against INSTI-resistant HIV-1 harboring integrase G118R mutant infected in human HOS cells pretreated with compound for 3 hrs by single-round HIV-1 infectivity assay, EC50 = 0.013 μM. 24901667
P4R5 MAGI Antiviral assay 24 hrs Antiviral activity against HIV1 infected in CD4/CXCR4/CCR5 expressing human P4R5 MAGI cells preincubated with cells for 24 hrs followed by viral infection measured after 48 hrs by beta-galactosidase reporter gene assay, EC50 = 0.02 μM. 30031976
P4R5 Antiviral assay 24 hrs Antiviral activity against HIV1 infected in CD4/CXCR4/CCR5 expressing human P4R5 cells assessed as inhibition of viral replication preincubated with cells for 24 hrs followed by viral infection measured after 48 hrs by beta-galactosidase reporter gene ass, EC50 = 0.02 μM. 28525279
HEK293T Antiviral assay 2 days Antiviral activity against pseudo Human immunodeficiency virus infected in HEK293T cells after 2 days in presence of human serum albumin, IC50 = 0.022 μM. 23845180
Vero E6 Antiviral assay 2 days Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days, EC50 = 22.04 μM. ChEMBL
Vero E6 Antiviral assay 2 days Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days, EC90 = 42.81 μM. ChEMBL
MDCK2 cells Function assay Inhibition of human OCT2 expressed in MDCK2 cells using [14C]metformin as substrate by liquid scintillation counting analysis 23132334
MDCK2 Function assay Inhibition of human OCT2 expressed in MDCK2 cells using [14C]metformin as substrate by liquid scintillation counting analysis, IC50 = 1.9 μM. 23132334
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明 Dolutegravir is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM in a cell-free assay, modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.
特性 A next-generation and two-metal-binding HIV integrase strand transfer inhibitor.
Targets
HIV integrase [2]
(Cell-free assay)
2.7 nM
In Vitro
In vitro

S/GSK1349572 shows the potent inhibitory effect on nine clinical isolates from integrase inhibitor-naive HIV-2-infected patients with EC50 ranging from 0.2 nM -1.4 nM. [1]

In vitro, S/GSK1349572 inhibits recombinant HIV-1 integrase-catalyzed strand transfer with IC50 of 2.7 nM. Furthermore, S/GSK1349572 potently inhibits HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector with EC50 of 0,51 nM, 0.71 nM and 2.2 nM, respectively. [2]

In vitro, S/GSK1349572 exhibits potent activity against five different nonnucleoside reverse transcription inhibitor--resistant or nucleoside reverse transcription inhibitor--resistant viruses with EC50 ranging from 1.3 nM -2.1 nM. Similarly to that against wild-type virus, S/GSK1349572 shows equivalent activity against two protease inhibitor-resistant viruses with EC50 of 0.36 nM and 0.37 nM, respectively. [2]

Kinase Assay In vitro strand transfer assay
The inhibitory potencies of S/GSK1349572 and other INIs are measured in a strand transfer assay using recombinant HIV integrase. A complex of integrase and biotinylated preprocessed donor DNA-streptavidin-coated Acintillation proximity assay (SPA) beads is formed by incubating 2 μM purified recombinant integrase with 0.66 μM biotinylated donor DNA-4 mg/mL streptavidin-coated SPA beads in 25 mM sodium morpholinepropanesulfonic acid (MOPS) (pH 7.2), 23 mM NaCl, and 10 mM MgCl2 for 5 minutes at 37 °C. These beads are spun down and preincubated with diluted INIs for 60 minutes at 37 °C. Then a 3H-labeled target DNA substrate is added to give a final concentration of 7 nM substrate, and the strand transfer reaction mixture is incubated at 37 °C for 25 to 45 minutes, which allows for a linear increase in the strand transfer of donor DNA to radiolabeled target DNA. The signal is read using a Wallac MicroBeta scintillation plate reader.
細胞実験 細胞株 MT-4
濃度 0 to 10 μM
反応時間 4 days or 5 days
実験の流れ

MT-4 cells growing exponentially at a density of 500000 or 600000 /mL are infected with HIV-1 strain IIIB at a viral multiplicity of infection of 0.001 or a 50% tissue culture infective dose of 4 to 10. The cells are then aliquoted to 96-well plates in the presence of varying concentrations of S/GSK1349572. After incubation for 4 or 5 days, antiviral activity is determined by a cell viability assay that either measured bioluminescence with a CellTiter-Glo luminescent reagent or measured absorbance at 560 and 690 nm using the yellow tetrazolium MTT reagent [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide].

実験結果図 Methods Biomarkers 結果図 PMID
Dose-response infectivity curves NL4.3IN(WT) / NL4.3IN(S230R) virus 29617824
In Vivo
In Vivo

Dolutegravir (DTG) is a first-line antiretroviral drug (ARV) used in combination therapy for HIV-1. It inhibits MMP activity and has the potential to affect prenatal and postnatal neurodevelopment.

動物実験 動物モデル C3H/HeJ mice
投与量 50 mg/kg
投与経路 o.g.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05069688 Recruiting
Pediatric HIV Infection|Tuberculosis Infection
Brigham and Women''s Hospital|APIN Public Health Initiatives|University of Cape Town
July 7 2023 Phase 1
NCT05122767 Recruiting
Tuberculosis|HIV
The Aurum Institute NPC|Johns Hopkins University
May 24 2023 Phase 1|Phase 2
NCT05122026 Not yet recruiting
HIV Seropositivity|Pregnancy|Tuberculosis Infection
The Aurum Institute NPC|Johns Hopkins University|Weill Medical College of Cornell University|University of Washington
January 30 2023 Phase 1|Phase 2

化学情報

分子量 419.38 化学式

C20H19F2N3O5

CAS No. 1051375-16-6 SDF Download Dolutegravir SDFをダウンロードする
Smiles CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O
保管

In vitro
Batch:

DMSO : 84 mg/mL ( (200.29 mM); Warmed with 50℃ water bath; 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: Dolutegravirを買う | Dolutegravir ic50 | Dolutegravir供給者 | Dolutegravirを購入する | Dolutegravir費用 | Dolutegravir生産者 | オーダーDolutegravir | Dolutegravir化学構造 | Dolutegravir分子量 | Dolutegravir代理店